Indication: Hematological Malignancies
A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLB
Sub-indication: Hematological Malignancies
Drug Study
Principal Investigator: Don Stevens, M.D.Norton Cancer Institute
Sponsor: Karyopharm Therapeutics Inc.
Email for more information: Heme-NCIResearch@nortonhealthcare.org
